Precision Medicine in Oncology® Articles

New Technology Eases Information Overload in Precision Medicine
R. Steven Paulson, MD, discusses how to adapt to the era of precision medicine, the latest with liquid biopsies, and a unique diagnostic tool with the potential to revolutionize oncology. 
Liquid Biopsies Are Shaping Future of Molecular Testing
Sreeni Chittoor, MD, FACP, discusses the role of liquid biopsies in non–small cell lung cancer and the advantages of using this type of assay compared with tissue-based genotyping across cancer types.  
Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC
Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting. 
Oncology Experts Preview Exciting Precision Medicine Research
Faculty from Texas Oncology and Quest Med Fusion highlight exciting ongoing research efforts at their respective institutions.
Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers
Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.
Technology Advances Aid Treatment Decisions for Community Oncologists
Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.
CFS<sup>®</sup> Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine
Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.
Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.
NGS Key to Guiding Treatment Decisions in <em>ALK</em>+ NSCLC
Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.
Larotrectinib Approved in Europe for NTRK+ Tumors
The European Commission has approved larotrectinib for the treatment of certain adult and pediatric patients with solid tumors who have an NTRK gene fusion without a known acquired resistance mutation.
Publication Bottom Border
Border Publication